BioXcel Therapeutics filed for Chapter 11 bankruptcy protection on August 27, 2026, and entered into a $77.25 million Super-Priority Senior Secured Priming Debtor-in-Possession Credit Agreement with Oaktree Capital Management affiliates and the Qatar Investment Authority. The facility includes up to $19 million in new money term loans and $58.25 million in roll-up loans converting prepetition debt, bearing 13% annual interest and maturing January 27, 2027. Concurrently, Nasdaq notified BioXcel of its common stock delisting effective September 8, 2026, due to the bankruptcy commencement, with shares expected to trade on the Pink Limited Market. The company operates in the biopharmaceutical industry.
